Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kukoamine B Mesilate in Sepsis Patients
NCT03237728Phase 1Completed
- Sponsor
- Tianjin Chase Sun Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Sep 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of kukoamine B in sepsis (4 arms), sponsored by Tianjin Chase Sun Pharmaceutical. Primary endpoint: Incidence of adverse events. Started Jul 2017; status: completed.
02
Drugs
kukoamine B
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT03237728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237728.